Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor Mutations
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Related studies linked through entity extraction aliases.